<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Tord Hompland | Theragnostic Imaging</title>
    <link>https://www.theragnostics.no/en/author/tord-hompland/</link>
      <atom:link href="https://www.theragnostics.no/en/author/tord-hompland/index.xml" rel="self" type="application/rss+xml" />
    <description>Tord Hompland</description>
    <generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Tue, 01 Nov 2022 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://www.theragnostics.no/media/icon_hu14557955862192370321.png</url>
      <title>Tord Hompland</title>
      <link>https://www.theragnostics.no/en/author/tord-hompland/</link>
    </image>
    
    <item>
      <title>Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer</title>
      <link>https://www.theragnostics.no/en/publications/skipar-2022-risk/</link>
      <pubDate>Tue, 01 Nov 2022 00:00:00 +0000</pubDate>
      <guid>https://www.theragnostics.no/en/publications/skipar-2022-risk/</guid>
      <description>&lt;hr&gt;
&lt;p&gt;MRI, applying dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) sequences, and 18F-fluorodeoxyglucose (18F-FDG) PET/CT provide information about tumor aggressiveness that is unexploited in treatment of locally advanced cervical cancer (LACC). We investigated the potential of a multimodal combination of imaging parameters for classifying patients according to their risk of recurrence. Eighty-two LACC patients with diagnostic MRI and FDG-PET/CT, treated with chemoradiotherapy, were collected. Thirty-eight patients with MRI only were included for validation of MRI results. Endpoints were survival (disease-free, cancer-specific, overall) and tumor control (local, locoregional, distant). K&lt;sup&gt;trans&lt;/sup&gt;, reflecting vascular function, apparent diffusion coefficient (ADC), reflecting cellularity, and standardized uptake value (SUV), reflecting glucose uptake, were extracted from DCE-MR, DW-MR and FDG-PET images, respectively. By applying an oxygen consumption and supply-based method, ADC and K&lt;sup&gt;trans&lt;/sup&gt; parametric maps were voxel-wise combined into hypoxia images that were used to determine hypoxic fraction (HF). HF showed a stronger association with outcome than the single modality parameters. This association was confirmed in the validation cohort. Low HF identified low-risk patients with 95% precision. Based on the 50th SUV-percentile (SUV&lt;sub&gt;50&lt;/sub&gt;), patients with high HF were divided into an intermediate- and high-risk group with high and low SUV&lt;sub&gt;50&lt;/sub&gt;, respectively. This defined a multimodality biomarker, HF/SUV&lt;sub&gt;50&lt;/sub&gt;. HF/SUV&lt;sub&gt;50&lt;/sub&gt; increased the precision of detecting high-risk patients from 41% (HF alone) to 57% and showed prognostic significance in multivariable analysis for all endpoints. Multimodal combination of MR- and FDG-PET/CT-images improves classification of LACC patients compared to single modality images and clinical factors.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
